Consolidated Statements of Operations - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Revenues:
Total revenue	$ 487,000	$ 525,000	$ 1,276,000	$ 2,228,000
Operating expenses:
Cost of product sales	(368,000)		(376,000)
Research and development expenses	(6,500,000)	(8,074,000)	(11,444,000)	(15,612,000)
Selling, general and administrative expenses	(8,072,000)	(13,427,000)	(24,097,000)	(26,836,000)
Total operating expenses	(14,940,000)	(21,501,000)	(35,917,000)	(42,448,000)
Loss from operations	(14,453,000)	(20,976,000)	(34,641,000)	(40,220,000)
Other income (expense):
Other income (expense), net	(634,000)	56,000	164,000	126,000
Interest income	16,000	72,000	80,000	82,000
Interest expense	(251,000)	(904,000)	(1,275,000)	(1,803,000)
Loss on extinguishment of debt			(2,757,000)
Loss before income taxes	(15,322,000)	(21,752,000)	(38,429,000)	(41,815,000)
Income tax benefit (expense)	(119,000)	45,000	(271,000)	(109,000)
Net loss	$ (15,441,000)	$ (21,707,000)	$ (38,700,000)	$ (41,924,000)
Loss per share
Basic and Diluted ($ per share)	$ (0.14)	$ (0.30)	$ (0.37)	$ (0.59)
Weighted average number of shares:
Basic and Diluted	112,778,258	72,526,441	103,686,706	70,624,583
Product revenue, net
Revenues:
Total revenue	$ (48,000)		$ 108,000
Collaboration revenue
Revenues:
Total revenue	7,000		152,000	$ 1,000,000
Research premium and grant revenue
Revenues:
Total revenue	$ 528,000	$ 525,000	$ 1,016,000	$ 1,228,000